R

ise and shine, everyone, another busy day is on the way. Yes, the peak vacation season is unfolding, but the world continues to spin, which means there is always much to do. This calls for a cup or three of stimulation — our flavor today is Southern pecan, for those keeping track — and, as always, we invite you to join us. Or hoist a bottle of water, if you prefer. As usual, here are some tidbits to help you along. Have a wonderful day and do keep in touch …

Novo Nordisk (NVO) may drop insulin prices in the U.S. next year as Sanofi (SNY) cuts prices of its own Lantus due to biosimilar competition, Pharmaphorum writes. Novo Nordisk expects average prices after rebates to be lower than levels in 2017 as prices of basal insulin are falling. Novo, Sanofi, and Eli Lilly (LLY) have been accused by lawmakers and in consumer lawsuits of collusion over high insulin prices. Novo maintains list prices have not kept up with rebates.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.